Faecal Microbiota Transplantation Reduces Lesion Severity and Medication Use in Canine Atopic Dermatitis: A Randomised, Placebo-Controlled, Double-Blinded Clinical Trial.

FMT safely reduces lesion severity and medication needs in canine atopic dermatitis.

This randomized, placebo-controlled, double-blinded clinical trial evaluated faecal microbiota transplantation (FMT) as adjunctive therapy for canine atopic dermatitis (cAD) in 40 client-owned dogs. Dogs received daily oral lyophilised FMT capsules for 90 days plus three monthly rectal administrations, or placebo equivalents. Primary outcomes measured included CADESI-04 scores, pruritus severity (PVAS), medication requirements, and owner-assessed treatment efficacy. FMT significantly reduced CADESI-04 scores at months 2 and 3 compared to placebo, with 35% of FMT-treated dogs achieving sustained ≥50% improvement versus only 5% in the placebo group. Medication scores were substantially lower in the FMT group at both month 2 and 3 assessments. Pruritus scores decreased similarly in both groups without significant between-group differences. Owner global assessment favored FMT treatment. The intervention was well-tolerated with no reported safety concerns. These findings demonstrate that adjunctive FMT represents a safe, microbiome-based therapeutic option for managing canine atopic dermatitis, potentially reducing reliance on symptomatic medications while improving clinical lesion severity.

This summary was distilled by AI and may occasionally misinterpret data. Confirm critical details with the primary literature before clinical application.